Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery

被引:19
|
作者
Taylor, NA
Liao, ZX
Stevens, C
Walsh, G
Roth, J
Putnam, J
Fossella, F
Allen, P
Cox, JD
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 56卷 / 03期
关键词
non-small-cell lung cancer; postoperative radiotherapy; induction chemotherapy; surgery;
D O I
10.1016/S0360-3016(03)00063-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the effectiveness of postoperative radiotherapy (RT) in patients with Stage IIB and Stage IIIA non-small-cell lung cancer (NSCLC) treated with induction chemotherapy followed by surgery. Methods and Materials: We retrospectively reviewed the treatment records of 98 patients (58 men and 40 women; median age 61 years, range 31-91) with Stage IIB and Stage IIIA NSCLC who were treated with induction chemotherapy followed by surgery at our institution between January 1990 and December 2000. Patients were grouped by treatment (chemotherapy/surgery alone vs. chemotherapy/surgery/RT), by disease stage and nodal classification. The rates of local control (LC), disease-specific survival, disease-free survival, and overall survival (OS) were calculated using the Kaplan-Meier method. Results: Of the 98 patients, 40 had Stage IIB and 58 had Stage IIIA. The clinical disease stage and N stage were significantly greater in those patients who underwent RT than in those who did not; however, no statistically significant differences were identified in the additional characteristics between those receiving and not receiving RT within each stage or nodal group. The overall 5-year actuarial LC rate was 81% in the RT group and 54% in the chemotherapy/surgery-alone group (p = 0.07). Postoperative RT significantly improved the 5-year LC rate in patients with Stage IIIA disease (from 35% to 82%,p = 0.01). Postoperative RT did not significantly improve the 5-year OS rate (30% with RT vs. 49% without) for all patients or for patients with Stage IIIA disease. The disease-specific survival and disease-free survival rates did not differ between the treatment groups. Patients who responded to induction chemotherapy had a significantly greater 5-year OS rate (49%) than did those with stable or progressive disease (22%, p = 0.003). Conclusion: Postoperative RT in patients with Stage IIIA NSCLC treated with induction chemotherapy followed by surgery significantly improved LC without improving OS. Significantly improved survival was observed in all patients who responded to induction chemotherapy compared with those with stable or progressive disease. (C) 2003 Elsevier Inc.
引用
收藏
页码:616 / 625
页数:10
相关论文
共 50 条
  • [21] Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff, Rene-Olivier
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (04)
  • [22] Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy
    Kramer, Gijsbert W. P. M.
    Legrand, Catherine L.
    van Schil, Paul
    Uitterhoeve, Lon
    Smit, Egbert F.
    Schramel, Franz
    Biesma, Bonne
    Tjan-Heijnen, Vivianne
    van Zandwijk, Nico
    Splinter, Ted
    Giaccone, Giuseppe
    van Meerbeeck, Jan P.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1391 - 1398
  • [23] Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer
    Mathisen, DJ
    Wain, JC
    Wright, C
    Choi, N
    Carey, R
    Hilgenberg, A
    Grossbard, M
    Lynch, T
    Grillo, H
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (01): : 123 - 131
  • [24] INFECTIONS IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
    FUKS, JZ
    PATEL, H
    HORNEDO, J
    VANECHO, DA
    MOODY, M
    AISNER, J
    MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (05): : 255 - 261
  • [25] Adjuvant Chemotherapy plus Radiotherapy is Superior to Chemotherapy in Surgically Treated IIIA N2 Non-Small-Cell Lung Cancer
    Xu, Xiao-Ling
    Chen, Wei
    Mao, Weimin
    Mao, Weimin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S446 - S446
  • [26] Stage IIIA non-small cell lung cancers treated with neoadjuvant concurrent chemotherapy and high dose radiotherapy followed by resection
    Shaikh, AY
    Haraf, DJ
    Salgia, R
    Hoffman, PC
    Ferguson, MK
    Connell, PP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S418 - S419
  • [27] Multicenter study on radiochemotherapy with paclitaxel in non-small-cell lung cancer - Induction chemotherapy followed by radiotherapy versus radiochemotherapy
    Willner, J
    Huber, RM
    Schmidt, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 19 - 19
  • [28] Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
    Lopez, S.
    CANCER RADIOTHERAPIE, 2008, 12 (05): : 500 - 501
  • [29] Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
    van Meerbeeck, Jan P.
    Kramer, Gijs W. P. M.
    Van Schil, Paul E. Y.
    Legrand, Catherine
    Smit, Egbert F.
    Schramel, Franz
    Tjan-Heijnen, Vivianne C.
    Biesma, Bonne
    Debruyne, Channa
    van Zandwijk, Nico
    Splinter, Ted A. W.
    Giaccone, Giuseppe
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (06): : 442 - 450
  • [30] Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer
    Jing, Xuquan
    Meng, Xue
    Sun, Xindong
    Yu, Jinming
    ONCOTARGETS AND THERAPY, 2016, 9 : 823 - 831